S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Context Therapeutics (CNTX) Earnings Date, Estimates & Call Transcripts

$1.32
-0.09 (-6.38%)
(As of 04/19/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 8Estimated
Actual EPS
(Mar. 21)
-$0.42 Missed By -$0.07
Consensus EPS
(Mar. 21)
-$0.35
Skip Charts & View Estimated and Actual Earnings Data

CNTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CNTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Context Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.23)($0.23)($0.23)
Q2 20241($0.27)($0.27)($0.27)
Q3 20241($0.28)($0.28)($0.28)
Q4 20241($0.31)($0.31)($0.31)
FY 20244($1.09)($1.09)($1.09)

CNTX Earnings Date and Information

Context Therapeutics last posted its earnings data on March 21st, 2024. The reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.07. Context Therapeutics has generated ($1.50) earnings per share over the last year (($1.50) diluted earnings per share). Earnings for Context Therapeutics are expected to grow in the coming year, from ($1.38) to ($0.71) per share. Context Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off prior year's report dates.

Context Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/8/2024
Estimated)
------- 
3/21/2024Q4 2023($0.35)($0.42)($0.07)($0.42)--
11/9/2023Q3 2023($0.30)($0.37)($0.07)($0.37)--
8/9/2023Q2 2023($0.20)($0.31)($0.11)($0.31)--
5/10/2023Q1 2023($0.19)($0.40)($0.21)($0.40)--
3/22/2023Q4 2022($0.30)($0.22)+$0.08($0.22)--
11/9/2022Q3 2022($0.25)($0.24)+$0.01($0.24)--
8/11/2022Q2 2022($0.25)($0.25)-($0.25)--
5/11/2022Q1 2022($0.24)($0.22)+$0.02($0.22)--
12/2/2021Q3 2021-($4.00)($4.00)($4.00)--

Context Therapeutics Earnings - Frequently Asked Questions

When is Context Therapeutics's earnings date?

Context Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off last year's report dates. Learn more on CNTX's earnings history.

Did Context Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Context Therapeutics (NASDAQ:CNTX) missed the analysts' consensus estimate of ($0.35) by $0.07 with a reported earnings per share (EPS) of ($0.42). Learn more on analysts' earnings estimate vs. CNTX's actual earnings.

How much profit does Context Therapeutics generate each year?

Context Therapeutics (NASDAQ:CNTX) has a recorded net income of -$23.96 million. CNTX has generated -$1.50 earnings per share over the last four quarters.

What is Context Therapeutics's EPS forecast for next year?

Context Therapeutics's earnings are expected to grow from ($1.38) per share to ($0.71) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:CNTX) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners